Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nurix Therapeutics, Inc. (NRIX)
USD23.25
+0.54 (+2.38%)
US NASDAQ Healthcare Biotechnology
Address
1600 Sierra Point Parkway 94005
Brisbane, CA, US
Brisbane, CA, US
CEO
Arthur T. Sands
Website
nurixtx.com
IPO
2020-07-24
CIK 1549595 ISIN US67080M1036
Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD23.25
+0.54 (+2.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.87
Float Shares
86.66M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.51% | +1.20% | +6.35% | +11.21% | +0.45% | -6.38% | +46.29% | +75.49% | -37.86% | -6.58% | -6.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (17 ratings, all time)
Buy
Price Targets & DCF
Current price
23.25
Low
28.00
+20.4%
Consensus
32.20
+38.5%
Median
32.00
+37.6%
High
36.00
+54.8%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 12 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
28.00
+20.4%
|
| Last Year | 19 |
28.95
+24.5%
|
| All Time | 37 |
28.81
+23.9%
|
Quality scores
Altman Z-Score
2.92
Grey zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+54.0% ★ Q2'26: -79.5% (vs Q2'25)
-
EPS growth Biotechnology: +29.7%-5.9% Q2'26: -55.8% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-346.8% Q2'26: -1,089.3% (vs Q2'25)
-
EBIT margin Biotechnology: +0.0%-314.0% Q2'26: +0.0% (vs Q2'25)
-
ROIC Biotechnology: -16.1%-17,167.8% Q2'26: +0.0% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%+29.1% Q2'26: +32.4% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.23× Q2'26: -0.15× (vs Q2'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Nov 2020 actual |
Nov 2021 actual |
Nov 2022 actual |
Nov 2023 actual |
Nov 2024 actual |
Nov 2025 actual |
Nov 2026 13 Rev. Ana. 12 EPS Ana. |
Nov 2027 12 Rev. Ana. 11 EPS Ana. |
Nov 2028 11 Rev. Ana. 10 EPS Ana. |
Nov 2029 5 Rev. Ana. 4 EPS Ana. |
Nov 2030 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.82M
est: 14.04M (+26.9%)
|
29.75M
est: 35.21M (-15.5%)
|
38.63M
est: 47.93M (-19.4%)
|
76.99M
est: 80.89M (-4.8%)
|
54.55M
est: 54.58M (-0.1%)
|
83.98M
est: 85.23M (-1.5%)
|
102.90M
89.07M – 133.24M
+20.7% YoY
|
76.29M
33.77M – 162.36M
-25.9% YoY
|
180.29M
180.27M – 180.31M
+136.3% YoY
|
251.94M
83.88M – 881.23M
+39.7% YoY
|
426.45M
141.98M – 1.49B
+69.3% YoY
|
| EBITDA |
-62.80M
est: -14.04M (-347.2%)
|
-115.07M
est: -93.08M (-23.6%)
|
-176.21M
est: -209.95M (+16.1%)
|
-137.82M
est: -80.89M (-70.4%)
|
-185.28M
est: -54.58M (-239.5%)
|
-244.84M
est: -85.23M (-187.3%)
|
-102.90M
-133.24M – -89.07M
-20.7% YoY
|
-76.29M
-162.36M – -33.77M
+25.9% YoY
|
-180.29M
-180.31M – -180.27M
-136.3% YoY
|
-251.94M
-881.23M – -83.88M
-39.7% YoY
|
-426.45M
-1.49B – -141.98M
-69.3% YoY
|
| EBIT |
-64.98M
est: -14.04M (-362.7%)
|
-117.06M
est: -98.58M (-18.8%)
|
-180.36M
est: -227.63M (+20.8%)
|
-143.95M
est: -80.89M (-78.0%)
|
-193.30M
est: -54.58M (-254.2%)
|
-263.70M
est: -85.23M (-209.4%)
|
-102.90M
-133.24M – -89.07M
-20.7% YoY
|
-76.29M
-162.36M – -33.77M
+25.9% YoY
|
-180.29M
-180.31M – -180.27M
-136.3% YoY
|
-251.94M
-881.23M – -83.88M
-39.7% YoY
|
-426.45M
-1.49B – -141.98M
-69.3% YoY
|
| Net Income |
-43.24M
est: -134.91M (+67.9%)
|
-117.19M
est: -98.03M (-19.5%)
|
-180.36M
est: -226.20M (+20.3%)
|
-143.95M
est: -144.73M (+0.5%)
|
-193.57M
est: -244.82M (+20.9%)
|
-264.46M
est: -250.04M (-5.8%)
|
-217.03M
-240.25M – -195.06M
+13.2% YoY
|
-213.60M
-271.58M – -155.63M
+1.6% YoY
|
-201.10M
-301.57M – 279.04M
+5.9% YoY
|
-126.64M
-537.85M – -16.82M
+37.0% YoY
|
-41.38M
-175.76M – -5.50M
+67.3% YoY
|
| SGA |
16.31M
est: 12.21M (+33.6%)
|
31.20M
est: 26.33M (+18.5%)
|
38.00M
est: 41.67M (-8.8%)
|
42.90M
est: 65.68M (-34.7%)
|
45.94M
est: 44.32M (+3.7%)
|
52.74M
est: 69.21M (-23.8%)
|
83.56M
72.32M – 108.20M
+20.7% YoY
|
61.95M
27.42M – 131.84M
-25.9% YoY
|
146.40M
146.38M – 146.42M
+136.3% YoY
|
204.58M
68.11M – 715.56M
+39.7% YoY
|
346.28M
115.29M – 1.21B
+69.3% YoY
|
| EPS |
-2.76
est: -2.01 (-37.3%)
|
-2.73
est: -2.54 (-7.3%)
|
-3.71
est: -3.55 (-4.6%)
|
-2.65
est: -2.65 (+0.1%)
|
-2.88
est: -2.81 (-2.5%)
|
-3.05
est: -3.04 (-0.3%)
|
-2.50
-2.77 – -2.25
+17.7% YoY
|
-2.39
-3.13 – -1.80
+4.6% YoY
|
-1.53
-3.48 – 3.22
+36.1% YoY
|
-1.46
-6.21 – -0.19
+4.3% YoY
|
-0.48
-2.03 – -0.06
+67.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-18 | BTIG | Buy | Buy | Maintain |
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-23 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-261.13M
OE per share TTM
-2.78
Owner's Yield
-13.36%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
69.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
197
Total invested
1.81B
Insider transactions (90d)
14
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52-0556948 | 4.87M | 10.90% | 1.09M | — | 4.87M | — | IA | Maryland | 2022-02-14 | ↗ |
| 2 | Wellington Group Holdings LLP | 3.48M | 5.41% | — | 2.64M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 3 | Wellington Investment Advisors Holdings LLP | 3.48M | 5.41% | — | 2.64M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 4 | Wellington Management Group LLP | 3.48M | 5.41% | — | 2.64M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 5 | Wellington Management Company LLP | 3.22M | 5.00% | — | 2.63M | — | — | IA | Massachusetts | 2024-11-08 | ↗ |
| 6 | ARK Investment Management LLC | 3.19M | 6.59% | 3.19M | — | 3.19M | — | IA | Delaware, United States | 2024-01-29 | ↗ |
| 7 | Morgan Stanley | 3.10M | 6.40% | — | 2.96M | — | 3.10M | HC, CO | Delaware. | 2024-02-09 | ↗ |
| 8 | David Kroin | 2.72M | 5.75% | — | 2.72M | — | — | HC, IN | United States | 2023-02-24 | ↗ |
| 9 | Deep Track Biotechnology Master Fund, Ltd. | 2.72M | 5.75% | — | 2.72M | — | — | CO | United States | 2023-02-24 | ↗ |
| 10 | Deep Track Capital, LP | 2.72M | 5.75% | — | 2.72M | — | — | IA, OO | United States | 2023-02-24 | ↗ |
| 11 | T. Sands | 2.71M | 5.40% | 2.71M | — | 2.71M | — | IN | States | 2024-02-14 | ↗ |
| 12 | The Vanguard Group - 23-1945930 | 2.60M | 5.36% | — | 21.7K | 2.56M | 40.9K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 13 | Robert I. Tepper | 2.55M | 5.70% | 128.2K | 2.42M | 128.2K | 2.42M | IN | — | 2022-02-14 | ↗ |
| 14 | Kevin P. Starr | 2.55M | 5.70% | 128.2K | 2.42M | 128.2K | 2.42M | IN | — | 2022-02-14 | ↗ |
| 15 | Wasatch Advisors LP 87-0319391 | 2.54M | 5.40% | 2.54M | — | 2.54M | — | IA | — | 2023-02-08 | ↗ |
| 16 | Mark Levin | 2.53M | 5.70% | 103.2K | 2.42M | 103.2K | 2.42M | IN | — | 2022-02-14 | ↗ |
| 17 | STATE STREET CORPORATION | 2.51M | 5.32% | — | 2.43M | — | 2.51M | HC | — | 2023-02-10 | ↗ |
| 18 | Baker Bros. Advisors (GP) LLC | 2.45M | 5.50% | 2.45M | — | 2.45M | — | HC, OO | — | 2022-02-14 | ↗ |
| 19 | Baker Bros. Advisors LP | 2.45M | 5.50% | 2.45M | — | 2.45M | — | IA, PN | — | 2022-02-14 | ↗ |
| 20 | Felix J. Baker | 2.45M | 5.50% | 2.45M | — | 2.45M | — | HC, IN | — | 2022-02-14 | ↗ |
| 21 | Julian C. Baker | 2.45M | 5.50% | 2.45M | — | 2.45M | — | HC, IN | — | 2022-02-14 | ↗ |
| 22 | TRV GP III, LLC | 2.42M | 5.40% | — | 2.42M | — | 2.42M | OO | — | 2022-02-14 | ↗ |
| 23 | Third Rock Ventures GP III, L.P. | 2.42M | 5.40% | — | 2.42M | — | 2.42M | PN | — | 2022-02-14 | ↗ |
| 24 | Third Rock Ventures III, L.P. | 2.42M | 5.40% | — | 2.42M | — | 2.42M | PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
197
+11 vs prev Q
New positions
43
Closed positions
30
Increased
110
Reduced
43
Put/Call ratio
0.06
Calls held
250.6K
Puts held
14.4K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 460.0K +460.0K (+100.0%) | 8.73B +8.7B (+100.0%) | 0.53% +0.531 pp | 2.58% +2.575 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 8.88M +2.1M (+31.2%) | 168.36M +105.9M (+169.4%) | 10.24% +2.205 pp | 0.00% +0.002 pp | USD21.15 -10.3% | 6 qtrs — |
| 3 | REDMILE GROUP, LLC | 8.09M +4.4M (+120.0%) | 153.54M +119.6M (+351.7%) | 9.34% +4.968 pp | 11.31% +8.000 pp | USD22.09 -14.1% | 22 qtrs — |
| 4 | DEEP TRACK CAPITAL, LP | 7.04M +979.4K (+16.2%) | 133.48M +77.5M (+138.5%) | 8.12% +0.922 pp | 2.38% +0.818 pp | USD13.70 +38.5% | 15 qtrs — |
| 5 | VANGUARD GROUP INC | 5.95M +1.5M (+32.5%) | 112.86M +71.4M (+172.1%) | 6.86% +1.531 pp | 0.00% +0.001 pp | USD22.20 -14.5% | 22 qtrs — |
| 6 | GENERAL ATLANTIC, L.P. | 4.90M +4.9M (+100.0%) | 92.90M +92.9M (+100.0%) | 5.65% +5.651 pp | 3.23% +3.234 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 7 | MORGAN STANLEY | 4.88M +2.6M (+115.9%) | 92.59M +71.7M (+343.3%) | 5.63% +2.946 pp | 0.01% +0.004 pp | USD15.19 +24.9% | 22 qtrs — |
| 8 | VESTAL POINT CAPITAL, LP | 4.69M +1.2M (+35.0%) | 88.97M +56.9M (+177.1%) | 5.41% +1.283 pp | 3.02% +1.575 pp | USD13.70 +38.5% | 7 qtrs — |
| 9 | BAKER BROS. ADVISORS LP | 4.66M +776.4K (+20.0%) | 88.37M +52.5M (+146.4%) | 5.38% +0.762 pp | 0.52% +0.258 pp | USD24.89 -23.8% | 22 qtrs — |
| 10 | FMR LLC | 4.23M -4.7M (-52.4%) | 80.32M -1.8M (-2.2%) | 4.89% -5.675 pp | 0.00% 0.000 pp | USD18.97 +0.0% | 22 qtrs — |
| 11 | STATE STREET CORP | 3.56M +697.1K (+24.4%) | 67.52M +41.1M (+155.3%) | 4.11% +0.706 pp | 0.00% +0.001 pp | USD17.06 +11.2% | 22 qtrs — |
| 12 | PERCEPTIVE ADVISORS LLC | 3.56M +2.1M (+151.1%) | 67.45M +54.4M (+415.5%) | 4.10% +2.420 pp | 1.20% +0.825 pp | USD16.38 +15.8% | 5 qtrs — |
| 13 | PICTET ASSET MANAGEMENT HOLDING SA | 3.47M +1.5M (+75.1%) | 65.78M +47.5M (+259.5%) | 3.65% +1.293 pp | 0.06% +0.046 pp | USD17.02 +11.5% | 10 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.25M +2.1M (+195.5%) | 61.62M +51.5M (+506.8%) | 3.75% +2.442 pp | 0.01% +0.006 pp | USD21.73 -12.7% | 22 qtrs — |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 3.21M +340.2K (+11.8%) | 60.93M +34.4M (+129.6%) | 3.71% +0.294 pp | 0.07% +0.024 pp | USD12.59 +50.7% | 5 qtrs — |
| 16 | DEUTSCHE BANK AG\ | 2.49M +1.0M (+72.8%) | 47.17M +33.9M (+254.8%) | 2.87% +1.160 pp | 0.02% +0.011 pp | USD13.94 +36.1% | 22 qtrs — |
| 17 | RUBRIC CAPITAL MANAGEMENT LP | 2.47M +2.5M (+100.0%) | 46.93M +46.9M (+100.0%) | 2.85% +2.855 pp | 0.56% +0.561 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 2.38M +502.3K (+26.7%) | 45.25M +27.9M (+160.1%) | 2.75% +0.515 pp | 0.00% +0.002 pp | USD20.06 -5.4% | 22 qtrs — |
| 19 | COMMODORE CAPITAL LP | 2.28M -1.5M (-39.8%) | 43.16M +8.2M (+23.6%) | 2.63% -1.867 pp | 2.87% +1.168 pp | USD18.63 +1.8% | 6 qtrs — |
| 20 | BRAIDWELL LP | 2.18M +2.2M (+100.0%) | 41.43M +41.4M (+100.0%) | 2.52% +2.520 pp | 1.32% +1.325 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 21 | KYNAM CAPITAL MANAGEMENT, LP | 1.97M -198.2K (-9.1%) | 37.38M +17.3M (+86.5%) | 2.27% -0.303 pp | 2.39% +0.896 pp | USD10.58 +79.3% | 4 qtrs — |
| 22 | ARK INVESTMENT MANAGEMENT LLC | 1.60M +92.1K (+6.1%) | 30.40M +16.4M (+117.8%) | 1.69% -0.109 pp | 0.20% +0.119 pp | USD11.91 +59.3% | 17 qtrs — |
| 23 | EVENTIDE ASSET MANAGEMENT, LLC | 1.30M +1.3M (+100.0%) | 24.62M +24.6M (+100.0%) | 1.50% +1.498 pp | 0.38% +0.385 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 24 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 1.29M -266.9K (-17.1%) | 24.48M +10.1M (+70.1%) | 1.36% -0.493 pp | 0.28% +0.144 pp | USD16.01 +18.5% | 6 qtrs — |
| 25 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.29M -266.9K (-17.1%) | 24.48M +10.1M (+70.1%) | 1.36% -0.493 pp | 0.01% +0.006 pp | USD16.01 +18.5% | 6 qtrs — |
| 26 | SOLEUS CAPITAL MANAGEMENT, L.P. | 1.22M -1.2M (-49.7%) | 23.13M +744.9K (+3.3%) | 1.28% -1.597 pp | 0.85% -0.274 pp | USD17.12 +10.8% | 10 qtrs — |
| 27 | CITADEL ADVISORS LLC | 1.15M +587.6K (+103.9%) | 21.87M +16.6M (+318.7%) | 1.33% +0.659 pp | 0.00% +0.003 pp | USD17.69 +7.2% | 22 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 1.08M +455.3K (+73.2%) | 20.44M +14.7M (+255.5%) | 1.24% +0.504 pp | 0.00% +0.002 pp | USD17.02 +11.5% | 21 qtrs — |
| 29 | AFFINITY ASSET ADVISORS, LLC | 967.6K +— (+0.0%) | 18.36M +9.4M (+105.3%) | 1.12% -0.033 pp | 1.05% +0.267 pp | USD12.10 +56.8% | 13 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 965.9K +101.5K (+11.7%) | 18.32M +10.3M (+129.4%) | 1.11% +0.087 pp | 0.00% +0.002 pp | USD16.02 +18.4% | 22 qtrs — |
| 31 | LONGAEVA PARTNERS L.P. | 927.7K +927.7K (+100.0%) | 17.60M +17.6M (+100.0%) | 1.07% +1.071 pp | 1.48% +1.476 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 32 | WOODLINE PARTNERS LP | 925.4K +848.9K (+1,109.0%) | 17.56M +16.8M (+2,382.2%) | 1.07% +0.977 pp | 0.07% +0.065 pp | USD19.14 -0.9% | 7 qtrs — |
| 33 | NORTHERN TRUST CORP | 805.7K +125.7K (+18.5%) | 15.28M +9.0M (+143.2%) | 0.93% +0.122 pp | 0.00% +0.001 pp | USD21.84 -13.1% | 22 qtrs — |
| 34 | NUVEEN, LLC | 784.4K +632.3K (+415.9%) | 14.88M +13.5M (+959.1%) | 0.91% +0.724 pp | 0.00% +0.004 pp | USD17.60 +7.8% | 4 qtrs — |
| 35 | BANK OF AMERICA CORP /DE/ | 736.6K +255.5K (+53.1%) | 13.97M +9.5M (+214.3%) | 0.85% +0.278 pp | 0.00% +0.001 pp | USD14.78 +28.3% | 22 qtrs — |
| 36 | JACOBS LEVY EQUITY MANAGEMENT, INC | 735.2K +691.3K (+1,576.1%) | 13.95M +13.5M (+3,341.0%) | 0.85% +0.796 pp | 0.05% +0.052 pp | USD18.39 +3.2% | 2 qtrs — |
| 37 | HANDELSBANKEN FONDER AB | 547.0K +27.0K (+5.2%) | 10.38M +5.6M (+116.0%) | 0.63% +0.013 pp | 0.03% +0.016 pp | USD10.82 +75.3% | 3 qtrs — |
| 38 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 537.5K +190.0K (+54.7%) | 10.20M +7.0M (+217.6%) | 0.62% +0.207 pp | 0.95% +0.598 pp | USD16.92 +12.1% | 7 qtrs — |
| 39 | CANDRIAM S.C.A. | 534.3K +271.9K (+103.6%) | 10.14M +7.7M (+318.1%) | 0.62% +0.305 pp | 0.05% +0.038 pp | USD20.73 -8.5% | 19 qtrs — |
| 40 | LOGOS GLOBAL MANAGEMENT LP | 500.0K +500.0K (+100.0%) | 9.49M +9.5M (+100.0%) | 0.58% +0.577 pp | 0.57% +0.573 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 41 | DIMENSIONAL FUND ADVISORS LP | 431.0K +24.0 (+0.0%) | 8.18M +4.2M (+105.3%) | 0.50% -0.015 pp | 0.00% +0.001 pp | USD12.48 +52.0% | 17 qtrs — |
| 42 | UBS GROUP AG | 423.4K +60.9K (+16.8%) | 8.03M +4.7M (+139.8%) | 0.49% +0.058 pp | 0.00% +0.001 pp | USD12.70 +49.4% | 20 qtrs — |
| 43 | INVESCO LTD. | 343.8K +183.9K (+115.0%) | 6.52M +5.0M (+341.4%) | 0.40% +0.207 pp | 0.00% +0.001 pp | USD16.12 +17.7% | 19 qtrs — |
| 44 | ARROWMARK COLORADO HOLDINGS LLC | 314.8K +— (+0.0%) | 5.97M +3.1M (+105.3%) | 0.36% -0.011 pp | 0.13% +0.077 pp | USD7.86 +141.3% | 10 qtrs — |
| 45 | BESSEMER GROUP INC | 306.0K +— (+0.0%) | 5.81M +3.0M (+105.3%) | 0.35% -0.011 pp | 0.01% +0.005 pp | USD28.36 -33.1% | 20 qtrs — |
| 46 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 300.0K -50.0K (-14.3%) | 5.69M +2.5M (+76.0%) | 0.35% -0.070 pp | 0.28% +0.064 pp | USD17.91 +5.9% | 7 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 288.1K +59.4K (+26.0%) | 5.47M +3.4M (+158.6%) | 0.30% +0.031 pp | 0.00% +0.001 pp | USD20.39 -7.0% | 22 qtrs — |
| 48 | WELLINGTON MANAGEMENT GROUP LLP | 275.2K +19.4K (+7.6%) | 5.22M +2.9M (+120.9%) | 0.32% +0.014 pp | 0.00% +0.001 pp | USD20.54 -7.6% | 22 qtrs — |
| 49 | KENNEDY CAPITAL MANAGEMENT LLC | 261.2K +14.5K (+5.9%) | 4.96M +2.7M (+117.3%) | 0.30% +0.008 pp | 0.10% +0.055 pp | USD13.57 +39.8% | 11 qtrs — |
| 50 | BARCLAYS PLC | 256.7K +128.3K (+100.0%) | 4.87M +2.0M (+68.8%) | 0.30% +0.144 pp | 0.00% +0.000 pp | USD17.23 +10.1% | 16 qtrs — |
| 51 | TD ASSET MANAGEMENT INC | 237.2K +237.2K (+100.0%) | 4.50M +4.5M (+100.0%) | 0.25% +0.249 pp | 0.00% +0.004 pp | USD18.97 +0.0% | 7 qtrs — |
| 52 | ENSIGN PEAK ADVISORS, INC | 230.8K +— (+0.0%) | 4.38M +2.2M (+105.3%) | 0.27% -0.008 pp | 0.01% +0.004 pp | USD19.86 -4.5% | 22 qtrs — |
| 53 | WESTHILL FINANCIAL ADVISORS, INC. | 228.3K +— (+0.0%) | 4.33M +2.2M (+105.3%) | 0.24% -0.031 pp | 0.82% +0.409 pp | USD29.96 -36.7% | 18 qtrs — |
| 54 | MILLENNIUM MANAGEMENT LLC | 179.8K -1.3M (-88.2%) | 3.41M -10.7M (-75.8%) | 0.21% -1.603 pp | 0.00% -0.005 pp | USD12.59 +50.7% | 21 qtrs — |
| 55 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 172.8K -1.0M (-85.6%) | 3.28M -7.8M (-70.4%) | 0.20% -1.223 pp | 0.00% -0.005 pp | USD20.77 -8.7% | 7 qtrs — |
| 56 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 172.4K +147.0K (+579.9%) | 3.28M +3.0M (+1,298.8%) | 0.20% +0.169 pp | 0.00% +0.003 pp | USD18.83 +0.7% | 22 qtrs — |
| 57 | CITIGROUP INC | 171.1K +163.7K (+2,222.5%) | 3.25M +3.2M (+4,668.3%) | 0.20% +0.189 pp | 0.00% +0.001 pp | USD18.88 +0.5% | 22 qtrs — |
| 58 | UBS ASSET MANAGEMENT AMERICAS INC | 168.8K +70.7K (+72.0%) | 3.20M +2.3M (+253.2%) | 0.19% +0.078 pp | 0.00% +0.001 pp | USD17.98 +5.5% | 7 qtrs — |
| 59 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 154.5K +5.3K (+3.6%) | 2.93M +1.6M (+112.6%) | 0.18% +0.001 pp | 0.01% +0.006 pp | USD11.88 +59.7% | 7 qtrs — |
| 60 | SWISS NATIONAL BANK | 150.0K +16.6K (+12.4%) | 2.85M +1.6M (+130.9%) | 0.16% -0.001 pp | 0.00% +0.001 pp | USD19.09 -0.6% | 7 qtrs — |
| 61 | BNP PARIBAS ARBITRAGE, SNC | 132.1K +57.6K (+77.3%) | 2.51M +1.8M (+264.0%) | 0.15% +0.064 pp | 0.00% +0.001 pp | USD14.98 +26.6% | 5 qtrs — |
| 62 | AMERIPRISE FINANCIAL INC | 124.7K +20.1K (+19.2%) | 2.37M +1.4M (+144.8%) | 0.14% +0.020 pp | 0.00% +0.000 pp | USD12.22 +55.2% | 13 qtrs — |
| 63 | SPHERA FUNDS MANAGEMENT LTD. | 124.0K +124.0K (+100.0%) | 2.35M +2.4M (+100.0%) | 0.14% +0.143 pp | 0.45% +0.455 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 64 | ALGERT GLOBAL LLC | 119.7K -444.2K (-78.8%) | 2.27M -2.9M (-56.4%) | 0.14% -0.532 pp | 0.04% -0.052 pp | USD9.68 +96.0% | 3 qtrs — |
| 65 | JANE STREET GROUP, LLC | 119.4K -139.2K (-53.8%) | 2.27M -124.8K (-5.2%) | 0.14% -0.170 pp | 0.00% +0.000 pp | USD9.24 +105.3% | 2 qtrs — |
| 66 | BURKEHILL GLOBAL MANAGEMENT, LP | 119.0K +119.0K (+100.0%) | 2.26M +2.3M (+100.0%) | 0.14% +0.137 pp | 0.15% +0.149 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 67 | RHUMBLINE ADVISERS | 118.6K +4.2K (+3.7%) | 2.25M +1.2M (+112.8%) | 0.14% +0.001 pp | 0.00% +0.001 pp | USD18.69 +1.5% | 22 qtrs — |
| 68 | BALYASNY ASSET MANAGEMENT L.P. | 118.5K -3.1K (-2.6%) | 2.25M +1.1M (+100.1%) | 0.14% -0.008 pp | 0.00% +0.001 pp | USD9.24 +105.3% | 2 qtrs — |
| 69 | WELLS FARGO & COMPANY/MN | 117.9K +57.2K (+94.1%) | 2.24M +1.7M (+298.6%) | 0.14% +0.064 pp | 0.00% +0.000 pp | USD16.47 +15.2% | 22 qtrs — |
| 70 | HUDSON BAY CAPITAL MANAGEMENT LP | 110.0K +110.0K (+100.0%) | 2.09M +2.1M (+100.0%) | 0.13% +0.127 pp | 0.01% +0.007 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 71 | BOXER CAPITAL MANAGEMENT, LLC | 100.0K -75.0K (-42.9%) | 1.90M +280.0K (+17.3%) | 0.12% -0.093 pp | 0.42% -0.100 pp | USD18.84 +0.7% | 5 qtrs — |
| 72 | ALLIANCEBERNSTEIN L.P. | 98.2K +34.9K (+55.1%) | 1.86M +1.3M (+218.4%) | 0.11% +0.038 pp | 0.00% +0.000 pp | USD15.78 +20.2% | 19 qtrs — |
| 73 | JASPER RIDGE PARTNERS, L.P. | 95.7K +— (+0.0%) | 1.82M +931.3K (+105.3%) | 0.11% -0.003 pp | 0.04% +0.020 pp | USD27.42 -30.8% | 20 qtrs — |
| 74 | RAFFERTY ASSET MANAGEMENT, LLC | 90.5K -1.9K (-2.1%) | 1.72M +862.9K (+101.0%) | 0.10% -0.005 pp | 0.01% +0.003 pp | USD14.29 +32.8% | 20 qtrs — |
| 75 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 86.4K +71.4K (+476.1%) | 1.64M +1.5M (+1,082.7%) | 0.10% +0.082 pp | 0.03% +0.023 pp | USD17.67 +7.4% | 8 qtrs — |
| 76 | VIENNA POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. VIENNA INSURANCE GROUP | 85.0K +— (+0.0%) | 1.61M +827.1K (+105.3%) | 0.09% -0.012 pp | 0.79% +0.323 pp | USD8.88 +113.6% | 12 qtrs — |
| 77 | LEGAL & GENERAL GROUP PLC | 85.0K +2.1K (+2.5%) | 1.61M +846.1K (+110.4%) | 0.09% -0.009 pp | 0.00% +0.000 pp | USD17.40 +9.0% | 22 qtrs — |
| 78 | JUMP FINANCIAL, LLC | 80.0K +80.0K (+100.0%) | 1.52M +1.5M (+100.0%) | 0.09% +0.092 pp | 0.02% +0.019 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 79 | EDMOND DE ROTHSCHILD HOLDING S.A. | 80.0K +80.0K (+100.0%) | 1.52M +1.5M (+100.0%) | 0.09% +0.092 pp | 0.02% +0.022 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 80 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 79.3K +39.2K (+97.8%) | 1.51M +1.1M (+306.0%) | 0.09% +0.044 pp | 0.00% +0.002 pp | USD19.49 -2.7% | 7 qtrs — |
| 81 | NEOS INVESTMENT MANAGEMENT LLC | 77.8K +33.0K (+73.9%) | 1.48M +1.1M (+257.0%) | 0.09% +0.037 pp | 0.01% +0.005 pp | USD15.93 +19.1% | 5 qtrs — |
| 82 | TREXQUANT INVESTMENT LP | 77.4K +62.5K (+419.2%) | 1.47M +1.3M (+965.9%) | 0.09% +0.072 pp | 0.01% +0.012 pp | USD17.51 +8.3% | 17 qtrs — |
| 83 | TEMA ETFS LLC | 76.6K +31.9K (+71.3%) | 1.45M +1.0M (+251.7%) | 0.08% +0.027 pp | 0.11% +0.079 pp | USD15.88 +19.5% | 5 qtrs — |
| 84 | WALLEYE CAPITAL LLC | 74.9K +74.9K (+100.0%) | 1.42M +1.4M (+100.0%) | 0.09% +0.086 pp | 0.00% +0.004 pp | USD18.97 +0.0% | 4 qtrs — |
| 85 | ADAR1 CAPITAL MANAGEMENT, LLC | 72.1K +40.9K (+131.0%) | 1.37M +1.1M (+374.2%) | 0.08% +0.046 pp | 0.10% +0.073 pp | USD16.89 +12.3% | 8 qtrs — |
| 86 | VERITION FUND MANAGEMENT LLC | 68.8K +68.8K (+100.0%) | 1.30M +1.3M (+100.0%) | 0.08% +0.079 pp | 0.01% +0.005 pp | USD18.97 +0.0% | 5 qtrs — |
| 87 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 68.0K +1.5K (+2.2%) | 1.29M +675.5K (+109.9%) | 0.08% -0.001 pp | 0.00% +0.001 pp | USD19.18 -1.1% | 22 qtrs — |
| 88 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 65.5K +22.8K (+53.3%) | 1.24M +848.3K (+214.7%) | 0.08% +0.025 pp | 0.09% +0.059 pp | USD13.60 +39.5% | 4 qtrs — |
| 89 | RUSSELL INVESTMENTS GROUP, LTD. | 63.5K +3.0K (+5.0%) | 1.20M +645.8K (+115.7%) | 0.07% +0.001 pp | 0.00% +0.001 pp | USD9.89 +91.8% | 14 qtrs — |
| 90 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 62.8K +62.8K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.07% +0.073 pp | 0.00% +0.000 pp | USD18.97 +0.0% | 1 qtrs NEW |
| 91 | POLYMER CAPITAL MANAGEMENT (HK) LTD | 58.9K +— (+0.0%) | 1.12M +573.1K (+105.3%) | 0.07% -0.002 pp | 0.16% +0.084 pp | USD17.80 +6.6% | 5 qtrs — |
| 92 | METLIFE INVESTMENT MANAGEMENT, LLC | 55.3K +10.1K (+22.4%) | 1.05M +632.1K (+151.3%) | 0.06% +0.010 pp | 0.01% +0.003 pp | USD20.53 -7.6% | 22 qtrs — |
| 93 | CINCTIVE CAPITAL MANAGEMENT LP | 47.7K -143.3K (-75.0%) | 905.0K -860.0K (-48.7%) | 0.06% -0.172 pp | 0.05% -0.035 pp | USD12.55 +51.2% | 6 qtrs — |
| 94 | JPMORGAN CHASE & CO | 47.3K -245.0 (-0.5%) | 897.1K +457.8K (+104.2%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD15.53 +22.2% | 22 qtrs — |
| 95 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 43.7K -2.9K (-6.1%) | 829.8K +399.1K (+92.7%) | 0.05% -0.009 pp | 0.00% +0.000 pp | USD9.75 +94.6% | 12 qtrs — |
| 96 | AMERICAN CENTURY COMPANIES INC | 42.9K +16.8K (+64.2%) | 813.4K +572.1K (+237.0%) | 0.05% +0.018 pp | 0.00% +0.000 pp | USD13.04 +45.5% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 101 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 2.40% | 31.43M | 0.75% |
| 2 | Global X HealthTech ETF HEAL | 1.95% | 584.9K | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.84% | 482.0K | 0.65% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.53% | 189.3K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.53% | 56.87M | 0.35% |
| 6 | iShares Micro-Cap ETF IWC | 0.50% | 7.41M | 0.60% |
| 7 | iShares Biotechnology ETF IBB | 0.17% | 16.33M | 0.44% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.17% | 122.5K | 0.35% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.17% | 1.83M | 0.35% |
| 10 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.16% | 759.0K | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
17
Sells
17
Shares acquired
275.8K
Shares disposed
70.4K
Cash buys
—
Cash sales
8.00
Net activity
+205,439
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | Saltzman Edward C | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | Lacey David L. | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | Kapur Anil | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | GREGORY JULIA P | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | DANSEY ROGER D | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-15 | Baynes Roy D. | Director | A-Award | A | Director Stock Option (right to buy) | 31,250 | 15.86 | 495.6K | 31,250 | D | ↗ |
| 2026-05-05 | van Houte Hans | Officer | S-Sale | D | Common Stock | 582 | 17.18 | 10.0K | 37,592 | D | ↗ |
| 2026-05-04 | Ring Christine | Officer | S-Sale | D | Common Stock | 8,148 | 16.96 | 138.2K | 18,305 | D | ↗ |
| 2026-05-01 | Ring Christine | Officer | S-Sale | D | Common Stock | 5,394 | 16.76 | 90.4K | 26,453 | D | ↗ |
| 2026-04-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | D | ↗ |
| 2026-04-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 28,453 | D | ↗ |
| 2026-04-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 0 | D | ↗ |
| 2026-04-02 | Ring Christine | Officer | S-Sale | D | Common Stock | 8,148 | 15.24 | 124.1K | 26,453 | D | ↗ |
| 2026-03-02 | Ring Christine | Officer | S-Sale | D | Common Stock | 8,148 | 15.44 | 125.8K | 34,601 | D | ↗ |
| 2026-02-10 | van Houte Hans | Officer | A-Award | A | Employee Stock Option (right to buy) | 93,750 | 16.45 | 1.54M | 93,750 | D | ↗ |
| 2026-02-10 | SANDS ARTHUR T | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 562,500 | 16.45 | 9.25M | 562,500 | D | ↗ |
| 2026-02-10 | Ring Christine | Officer | A-Award | A | Restricted Stock Units | 42,875 | 0.00 | — | 42,875 | D | ↗ |
| 2026-02-10 | Hansen Gwenn | Officer | A-Award | A | Employee Stock Option (right to buy) | 93,750 | 16.45 | 1.54M | 93,750 | D | ↗ |
| 2026-02-09 | Ring Christine | Officer | S-Sale | D | Common Stock | 14,261 | 16.66 | 237.6K | 42,749 | D | ↗ |
| 2026-02-03 | Hansen Gwenn | Officer | M-Exempt | A | Common Stock | 31,333 | 0.84 | 26.3K | 115,005 | D | ↗ |
| 2026-01-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,887 | 0.00 | — | 40,479 | D | ↗ |
| 2026-01-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 3,750 | 0.00 | — | 18,750 | D | ↗ |
| 2026-01-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 98 | 17.37 | 1.7K | 83,672 | D | ↗ |
| 2026-01-20 | Ring Christine | Officer | M-Exempt | A | Common Stock | 3,760 | 1.86 | 7.0K | 54,657 | D | ↗ |
| 2025-12-18 | Ring Christine | Officer | S-Sale | D | Common Stock | 3,560 | 17.87 | 63.6K | 51,097 | D | ↗ |
| 2025-11-24 | Ring Christine | Officer | M-Exempt | A | Common Stock | 37,600 | 1.86 | 69.9K | 88,497 | D | ↗ |
| 2025-11-06 | DANSEY ROGER D | Director | A-Award | A | Director Stock Option (right to buy) | 50,000 | 12.52 | 626.0K | 50,000 | D | ↗ |
| 2025-11-03 | van Houte Hans | Officer | S-Sale | D | Common Stock | 6,284 | 12.56 | 78.9K | 37,592 | D | ↗ |
| 2025-10-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | D | ↗ |
| 2025-10-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 3,750 | 0.00 | — | 22,500 | D | ↗ |
| 2025-10-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 4,087 | 12.80 | 52.3K | 76,751 | D | ↗ |
| 2025-10-14 | Hansen Gwenn | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2025-09-17 | GREGORY JULIA P | Director | M-Exempt | A | Common Stock | 10,750 | 1.86 | 20.0K | 10,750 | D | ↗ |
| 2025-08-01 | van Houte Hans | Officer | S-Sale | D | Common Stock | 5,402 | 11.03 | 59.6K | 35,512 | D | ↗ |
| 2025-07-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,858 | 0.00 | — | 31,442 | D | ↗ |
| 2025-07-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 1,924 | 0.00 | — | 39,242 | D | ↗ |
| 2025-07-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 3,207 | 0.00 | — | 6,414 | D | ↗ |
| 2025-05-19 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Saltzman Edward C | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Lacey David L. | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Kunkel Lori Anne | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Kapur Anil | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | GREGORY JULIA P | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-19 | Baynes Roy D. | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.51 | 237.8K | 25,000 | D | ↗ |
| 2025-05-02 | van Houte Hans | Officer | S-Sale | D | Common Stock | 6,198 | 11.33 | 70.2K | 33,724 | D | ↗ |
| 2025-04-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,886 | 0.00 | — | 8,659 | D | ↗ |
| 2025-04-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 1,924 | 0.00 | — | 34,462 | D | ↗ |
| 2025-04-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 3,206 | 0.00 | — | 9,621 | D | ↗ |
| 2025-03-11 | Baynes Roy D. | Director | A-Award | A | Director Stock Option (right to buy) | 50,000 | 13.90 | 695.0K | 50,000 | D | ↗ |
| 2025-03-03 | van Houte Hans | Officer | S-Sale | D | Common Stock | 5,125 | 14.40 | 73.8K | 34,424 | D | ↗ |
| 2025-02-11 | van Houte Hans | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 17.12 | 1.28M | 75,000 | D | ↗ |
| 2025-02-11 | SANDS ARTHUR T | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 450,000 | 17.12 | 7.70M | 450,000 | D | ↗ |
| 2025-02-11 | Ring Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 17.12 | 1.28M | 75,000 | D | ↗ |
| 2025-02-11 | Hansen Gwenn | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 17.12 | 1.28M | 75,000 | D | ↗ |
| 2025-01-31 | Ring Christine | Officer | M-Exempt | A | Common Stock | 223 | 1.86 | 414.78 | 32,761 | D | ↗ |
| 2025-01-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-01-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 1,924 | 0.00 | — | 7,697 | D | ↗ |
| 2025-01-30 | Hansen Gwenn | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 55,877 | D | ↗ |
| 2025-01-02 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,760 | 1.86 | 10.7K | 53,986 | D | ↗ |
| 2024-12-02 | Ring Christine | Officer | M-Exempt | A | Common Stock | 5,760 | 1.86 | 10.7K | 33,844 | D | ↗ |
| 2024-11-04 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,290 | 9.57 | 31.5K | 96,389 | D | ↗ |
| 2024-11-01 | van Houte Hans | Officer | S-Sale | D | Common Stock | 3,546 | 24.28 | 86.1K | 33,724 | D | ↗ |
| 2024-11-01 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,760 | 1.86 | 10.7K | 65,506 | D | ↗ |
| 2024-10-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,886 | 0.00 | — | 14,431 | D | ↗ |
| 2024-10-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 28,516 | D | ↗ |
| 2024-10-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 3,207 | 0.00 | — | 16,034 | D | ↗ |
| 2024-10-15 | Kapur Anil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-14 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,290 | 9.57 | 31.5K | 99,679 | D | ↗ |
| 2024-10-01 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,760 | 1.86 | 10.7K | 71,266 | D | ↗ |
| 2024-09-03 | Ring Christine | Officer | S-Sale | D | Common Stock | 200 | 25.62 | 5.1K | 24,592 | — | ↗ |
| 2024-08-26 | van Houte Hans | Officer | S-Sale | D | Common Stock | 20,000 | 25.22 | 504.4K | 31,002 | — | ↗ |
| 2024-08-26 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,407 | 9.57 | 51.7K | 106,259 | — | ↗ |
| 2024-08-01 | van Houte Hans | Officer | S-Sale | D | Common Stock | 3,377 | 21.43 | 72.4K | 51,102 | — | ↗ |
| 2024-08-01 | Ring Christine | Officer | M-Exempt | A | Common Stock | 5,760 | 1.86 | 10.7K | 30,352 | — | ↗ |
| 2024-07-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 53,219 | — | ↗ |
| 2024-07-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 1,924 | 0.00 | — | 11,545 | — | ↗ |
| 2024-07-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 14,000 | — | ↗ |
| 2024-07-17 | Kunkel Lori Anne | Director | G-Gift | D | Common Stock | 54,027 | 0.00 | — | 0 | — | ↗ |
| 2024-07-01 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 5,760 | 1.86 | 10.7K | 88,546 | — | ↗ |
| 2024-06-20 | van Houte Hans | Officer | S-Sale | D | Common Stock | 20,000 | 20.01 | 400.2K | 48,333 | — | ↗ |
| 2024-06-13 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,864 | 1.86 | 3.5K | 94,306 | — | ↗ |
| 2024-06-12 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,900 | 17.01 | 32.3K | 19,838 | — | ↗ |
| 2024-06-05 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 1.86 | 744.00 | 98,070 | — | ↗ |
| 2024-06-03 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,596 | 1.86 | 3.0K | 98,470 | — | ↗ |
| 2024-05-20 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-20 | Saltzman Edward C | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-20 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-20 | Lacey David L. | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-20 | Kunkel Lori Anne | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-20 | GREGORY JULIA P | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 16.19 | 404.8K | 25,000 | — | ↗ |
| 2024-05-02 | van Houte Hans | Officer | S-Sale | D | Common Stock | 3,499 | 12.83 | 44.9K | 68,333 | — | ↗ |
| 2024-04-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 16,000 | — | ↗ |
| 2024-04-30 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,513 | 12.04 | 18.2K | 19,838 | — | ↗ |
| 2024-04-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 2,007 | 12.04 | 24.2K | 39,601 | — | ↗ |
| 2024-02-16 | van Houte Hans | Officer | S-Sale | D | Common Stock | 6,812 | 10.02 | 68.2K | 68,333 | — | ↗ |
| 2024-02-13 | van Houte Hans | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2024-02-13 | SANDS ARTHUR T | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 800,000 | 8.72 | 6.98M | 800,000 | — | ↗ |
| 2024-02-13 | Ring Christine | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2024-02-13 | Hansen Gwenn | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2024-01-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 18,000 | — | ↗ |
| 2024-01-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 1,924 | 0.00 | — | 15,393 | — | ↗ |
| 2024-01-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 18,000 | — | ↗ |
| 2023-12-20 | van Houte Hans | Officer | S-Sale | D | Common Stock | 3,541 | 10.00 | 35.4K | 71,930 | — | ↗ |
| 2023-12-19 | van Houte Hans | Officer | S-Sale | D | Common Stock | 10,906 | 10.00 | 109.1K | 75,471 | — | ↗ |
| 2023-10-31 | van Houte Hans | Officer | S-Sale | D | Common Stock | 1,080 | 5.20 | 5.6K | 86,377 | — | ↗ |
| 2023-10-31 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,232 | 5.20 | 6.4K | 15,263 | — | ↗ |
| 2023-10-31 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,633 | 5.20 | 8.5K | 33,529 | — | ↗ |
| 2023-10-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 87,457 | — | ↗ |
| 2023-10-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-10-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-07-31 | van Houte Hans | Officer | S-Sale | D | Common Stock | 1,245 | 9.65 | 12.0K | 82,571 | — | ↗ |
| 2023-07-31 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,420 | 9.65 | 13.7K | 12,544 | — | ↗ |
| 2023-07-31 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,884 | 9.65 | 18.2K | 29,955 | — | ↗ |
| 2023-07-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 83,816 | — | ↗ |
| 2023-07-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 1,924 | 0.00 | — | 11,964 | — | ↗ |
| 2023-07-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 22,000 | — | ↗ |
| 2023-05-04 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-04 | Saltzman Edward C | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-04 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-04 | Lacey David L. | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-04 | Kunkel Lori Anne | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-04 | GREGORY JULIA P | Director | A-Award | A | Director Stock Option (right to buy) | 25,000 | 9.44 | 236.0K | 25,000 | — | ↗ |
| 2023-05-01 | van Houte Hans | Officer | S-Sale | D | Common Stock | 721 | 9.88 | 7.1K | 78,930 | — | ↗ |
| 2023-05-01 | Wolff Stefani | Officer | S-Sale | D | Common Stock | 342 | 9.88 | 3.4K | 6,113 | — | ↗ |
| 2023-05-01 | Ring Christine | Officer | S-Sale | D | Common Stock | 682 | 9.88 | 6.7K | 10,040 | — | ↗ |
| 2023-05-01 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,136 | 9.88 | 11.2K | 26,632 | — | ↗ |
| 2023-04-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,886 | 0.00 | — | 79,651 | — | ↗ |
| 2023-04-30 | Wolff Stefani | Officer | M-Exempt | D | Restricted Stock Units | 962 | 0.00 | — | 10,582 | — | ↗ |
| 2023-04-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 1,924 | 0.00 | — | 21,165 | — | ↗ |
| 2023-04-30 | Hansen Gwenn | Officer | M-Exempt | D | Restricted Stock Units | 3,206 | 0.00 | — | 35,275 | — | ↗ |
| 2023-02-14 | van Houte Hans | Officer | A-Award | A | Employee Stock Option (right to buy) | 88,900 | 10.83 | 962.8K | 88,900 | — | ↗ |
| 2023-02-14 | Wolff Stefani | Officer | A-Award | A | Restricted Stock Units | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2023-02-14 | SANDS ARTHUR T | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 448,000 | 10.83 | 4.85M | 448,000 | — | ↗ |
| 2023-02-14 | Ring Christine | Officer | A-Award | A | Restricted Stock Units | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2023-02-14 | Hansen Gwenn | Officer | A-Award | A | Restricted Stock Units | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2023-01-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,886 | 0.00 | — | 34,633 | — | ↗ |
| 2023-01-30 | Wolff Stefani | Officer | M-Exempt | D | Restricted Stock Units | 962 | 0.00 | — | 11,544 | — | ↗ |
| 2023-01-30 | Ring Christine | Officer | M-Exempt | D | Restricted Stock Units | 1,924 | 0.00 | — | 23,089 | — | ↗ |
| 2023-01-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,412 | 11.78 | 16.6K | 23,009 | — | ↗ |
| 2022-10-31 | van Houte Hans | Officer | S-Sale | D | Common Stock | 739 | 12.88 | 9.5K | 74,803 | — | ↗ |
| 2022-10-31 | Wolff Stefani | Officer | S-Sale | D | Common Stock | 350 | 12.88 | 4.5K | 3,402 | — | ↗ |
| 2022-10-31 | Ring Christine | Officer | S-Sale | D | Common Stock | 699 | 12.88 | 9.0K | 6,185 | — | ↗ |
| 2022-10-31 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,165 | 12.88 | 15.0K | 21,214 | — | ↗ |
| 2022-10-30 | van Houte Hans | Officer | M-Exempt | D | Restricted Stock Units | 2,886 | 0.00 | — | 37,519 | — | ↗ |
| 2022-10-30 | Wolff Stefani | Officer | M-Exempt | A | Common Stock | 962 | 0.00 | — | 3,752 | — | ↗ |
| 2022-10-30 | Ring Christine | Officer | M-Exempt | A | Common Stock | 1,924 | 0.00 | — | 6,884 | — | ↗ |
| 2022-10-30 | Hansen Gwenn | Officer | M-Exempt | A | Common Stock | 3,207 | 0.00 | — | 22,379 | — | ↗ |
| 2022-09-12 | Saltzman Edward C | Director | A-Award | A | Director Stock Option (right to buy) | 50,000 | 16.29 | 814.5K | 50,000 | — | ↗ |
| 2022-08-09 | van Houte Hans | Officer | A-Award | A | Employee Stock Option (right to buy) | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2022-08-09 | Wolff Stefani | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,375 | 0.00 | — | 110,375 | — | ↗ |
| 2022-08-09 | SANDS ARTHUR T | Officer | A-Award | A | Employee Stock Option (right to buy) | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2022-08-09 | Ring Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,199 | 0.00 | — | 40,199 | — | ↗ |
| 2022-08-09 | Hansen Gwenn | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,298 | 0.00 | — | 60,298 | — | ↗ |
| 2022-07-30 | van Houte Hans | Officer | S-Sale | D | Common Stock | 752 | 15.67 | 11.8K | 72,656 | — | ↗ |
| 2022-07-30 | Wolff Stefani | Officer | S-Sale | D | Common Stock | 356 | 15.67 | 5.6K | 1,238 | — | ↗ |
| 2022-07-30 | Ring Christine | Officer | S-Sale | D | Common Stock | 712 | 15.67 | 11.2K | 4,615 | — | ↗ |
| 2022-07-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,186 | 15.67 | 18.6K | 19,172 | — | ↗ |
| 2022-05-31 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 68,333 | 0.84 | 57.4K | 70,522 | — | ↗ |
| 2022-05-05 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-05-05 | SIEGALL CLAY B | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-05-05 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-05-05 | Lacey David L. | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-05-05 | Kunkel Lori Anne | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-05-05 | GREGORY JULIA P | Director | A-Award | A | Director Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-04-30 | van Houte Hans | Officer | M-Exempt | A | Common Stock | 2,886 | 0.00 | — | 2,886 | — | ↗ |
| 2022-04-30 | Wolff Stefani | Officer | S-Sale | D | Common Stock | 330 | 11.75 | 3.9K | 632 | — | ↗ |
| 2022-04-30 | Ring Christine | Officer | S-Sale | D | Common Stock | 660 | 11.75 | 7.8K | 3,403 | — | ↗ |
| 2022-04-30 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 1,098 | 11.75 | 12.9K | 17,151 | — | ↗ |
| 2022-01-20 | SANDS ARTHUR T | Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 18.89 | 5.67M | 300,000 | — | ↗ |
| 2022-01-19 | van Houte Hans | Officer | A-Award | A | Employee Stock Option (right to buy) | 103,894 | 19.49 | 2.02M | 103,894 | — | ↗ |
| 2022-01-19 | Wolff Stefani | Officer | A-Award | A | Employee Stock Option (right to buy) | 34,631 | 19.49 | 675.0K | 34,631 | — | ↗ |
| 2022-01-19 | Ring Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 69,262 | 19.49 | 1.35M | 69,262 | — | ↗ |
| 2022-01-19 | Hansen Gwenn | Officer | A-Award | A | Employee Stock Option (right to buy) | 115,438 | 19.49 | 2.25M | 115,438 | — | ↗ |
| 2022-01-10 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,200 | 27.14 | 32.6K | 1,286 | — | ↗ |
| 2022-01-03 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 7.26 | 2.9K | 67,466 | — | ↗ |
| 2021-12-10 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,200 | 1.86 | 2.2K | 101,266 | — | ↗ |
| 2021-12-01 | Hansen Gwenn | Officer | M-Exempt | A | Common Stock | 400 | 7.26 | 2.9K | 14,597 | — | ↗ |
| 2021-11-10 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,200 | 1.86 | 2.2K | 102,466 | — | ↗ |
| 2021-11-01 | Hansen Gwenn | Officer | M-Exempt | A | Common Stock | 400 | 7.26 | 2.9K | 14,597 | — | ↗ |
| 2021-10-27 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 800 | 1.86 | 1.5K | 103,666 | — | ↗ |
| 2021-10-27 | Hansen Gwenn | Officer | S-Sale | D | Common Stock | 400 | 35.00 | 14.0K | 14,197 | — | ↗ |
| 2021-10-11 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,200 | 1.86 | 2.2K | 104,466 | — | ↗ |
| 2021-10-01 | Silva Paul M | Director | A-Award | A | Director Stock Option (right to buy) | 35,000 | 31.24 | 1.09M | 35,000 | — | ↗ |
| 2021-10-01 | Reinsdorf Judith A | Director | A-Award | A | Director Stock Option (right to buy) | 35,000 | 31.24 | 1.09M | 35,000 | — | ↗ |
| 2021-10-01 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 7.26 | 2.9K | 69,066 | — | ↗ |
| 2021-09-10 | Ring Christine | Officer | S-Sale | D | Common Stock | 800 | 36.76 | 29.4K | 1,286 | — | ↗ |
| 2021-09-07 | Ring Christine | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,200 | 1.86 | 6.0K | 107,666 | — | ↗ |
| 2021-09-07 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,600 | 7.26 | 11.6K | 69,466 | — | ↗ |
| 2021-09-01 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 7.26 | 2.9K | 71,066 | — | ↗ |
| 2021-08-16 | Wolff Stefani | Officer | — | D | Employee Stock Option (right to buy) | 443,865 | 23.23 | 10.31M | 0 | — | ↗ |
| 2021-08-10 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,200 | 29.87 | 35.8K | 805 | — | ↗ |
| 2021-08-10 | Beaurang Pierre | Officer | M-Exempt | A | Common Stock | 7,500 | 1.11 | 8.3K | 11,830 | — | ↗ |
| 2021-08-02 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 7.26 | 2.9K | 71,466 | — | ↗ |
| 2021-07-20 | Ring Christine | Officer | S-Sale | D | Common Stock | 1,200 | 27.00 | 32.4K | 805 | — | ↗ |
| 2021-07-12 | Beaurang Pierre | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 7,500 | 1.11 | 8.3K | 14,062 | — | ↗ |
| 2021-07-01 | Hansen Gwenn | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 400 | 7.26 | 2.9K | 71,866 | — | ↗ |
| 2021-06-10 | Ring Christine | Officer | S-Sale | D | Common Stock | 200 | 30.52 | 6.1K | 805 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-8.4K
Shares Outstanding
86.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Arthur T. Sands President, Chief Executive Officer and Director | 674.6K | — | — | 5.17M | 510.0K | 23.4K | 6.37M | 81.05% | ↗ |
| 2 | 2025 | Gwenn M. Hansen Chief Scientific Officer | 556.0K | — | 770.8K | 861.0K | 307.4K | 2.8K | 2.50M | 65.32% | ↗ |
| 3 | 2025 | Hans van Houte Chief Financial Officer | 545.8K | — | 587.2K | 861.0K | 298.2K | 4.2K | 2.30M | 63.06% | ↗ |
| 4 | 2025 | Christine Ring Chief Legal Officer and Chief Compliance Officer | 527.5K | — | 587.2K | 861.0K | 283.8K | 3.8K | 2.26M | 63.99% | ↗ |
| 5 | 2024 | Arthur T. Sands President, Chief Executive Officer and Director | 613.1K | — | — | 4.75M | 424.4K | 23.7K | 5.81M | 81.74% | ↗ |
| 6 | 2024 | Gwenn M. Hansen Chief Scientific Officer | 510.5K | — | 392.4K | 890.9K | 235.5K | 4.5K | 2.03M | 63.10% | ↗ |
| 7 | 2024 | Christine Ring Chief Legal Officer and Chief Compliance Officer | 498.7K | — | 392.4K | 890.9K | 230.0K | 4.5K | 2.02M | 63.64% | ↗ |
| 8 | 2024 | Hans van Houte Chief Financial Officer | 498.7K | — | 392.4K | 890.9K | 230.0K | 4.5K | 2.02M | 63.64% | ↗ |
| 9 | 2023 | Arthur T. Sands President, Chief Executive Officer and Director | 590.8K | — | — | 3.38M | 355.4K | 40.2K | 4.36M | 77.39% | ↗ |
| 10 | 2023 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 590.8K | — | — | 3.38M | 355.4K | 40.2K | 4.36M | 77.39% | ↗ |
| 11 | 2023 | Gwenn M. Hansen, Ph.D. Chief Scientific Officer | 493.2K | — | 259.9K | 670.1K | 203.7K | 5.9K | 1.63M | 56.96% | ↗ |
| 12 | 2023 | Gwenn M. Hansen Chief Scientific Officer | 493.2K | — | 259.9K | 670.1K | 203.7K | 5.9K | 1.63M | 56.96% | ↗ |
| 13 | 2023 | Hans van Houte Chief Financial Officer | 482.9K | — | 259.9K | 670.1K | 193.6K | 5.4K | 1.61M | 57.69% | ↗ |
| 14 | 2022 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 572.1K | — | — | 8.51M | 293.3K | 45.6K | 9.42M | 90.33% | ↗ |
| 15 | 2022 | Arthur T. Sands President, Chief Executive Officer and Director | 572.1K | — | — | 8.51M | 293.3K | 45.6K | 9.42M | 90.33% | ↗ |
| 16 | 2022 | Hans van Houte Chief Financial Officer | 465.4K | — | 900.0K | 2.76M | 171.1K | 14.2K | 4.31M | 84.89% | ↗ |
| 17 | 2022 | Gwenn M. Hansen Chief Scientific Officer | 476.3K | — | 1,000.0K | 2.16M | 180.5K | 4.5K | 3.82M | 82.71% | ↗ |
| 18 | 2022 | Gwenn M. Hansen, Ph.D. Chief Scientific Officer | 476.3K | — | 1,000.0K | 2.16M | 180.5K | 4.5K | 3.82M | 82.71% | ↗ |
| 19 | 2021 | Stefani A. Wolff Chief Operating Officer and Executive Vice President, Product Development | 164.6K | 150.0K | — | 6.76M | 67.8K | 4.9K | 7.15M | 94.58% | ↗ |
| 20 | 2021 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 538.8K | — | — | 3.95M | 297.0K | 6.7K | 4.79M | 82.42% | ↗ |
| 21 | 2021 | Gwenn M. Hansen, Ph.D. Chief Scientific Officer | 433.8K | 97.6K | — | 1.58M | 186.2K | 6.2K | 2.30M | 68.58% | ↗ |
| 22 | 2021 | Hans van Houte Chief Financial Officer | 413.8K | — | — | 1.05M | 175.1K | 18.0K | 1.66M | 63.44% | ↗ |
| 23 | 2021 | Christine Ring, Ph.D., J.D. General Counsel and Secretary | 413.8K | — | — | 1.05M | 177.6K | 4.5K | 1.65M | 63.86% | ↗ |
| 24 | 2020 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 521.2K | — | — | 16.02M | 328.1K | 3.5K | 16.87M | 94.94% | ↗ |
| 25 | 2020 | Gwenn Hansen, Ph.D. Chief Scientific Officer | 391.3K | 97.6K | — | 878.7K | 181.5K | 3.5K | 1.55M | 56.60% | ↗ |
| 26 | 2020 | Gwenn M. Hansen, Ph.D. Chief Scientific Officer | 391.3K | 97.6K | — | 878.7K | 181.5K | 3.5K | 1.55M | 56.60% | ↗ |
| 27 | 2020 | Christine Ring, Ph.D., J.D. General Counsel | 376.3K | — | — | 758.6K | 168.7K | 3.5K | 1.31M | 58.04% | ↗ |
| 28 | 2020 | Christine Ring, Ph.D., J.D. General Counsel and Secretary | 376.3K | — | — | 758.6K | 168.7K | 3.5K | 1.31M | 58.04% | ↗ |
| 29 | 2019 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 477.8K | 400.0K | — | 352.3K | — | 251.5K | 1.48M | 23.78% | ↗ |
| 30 | 2019 | Gwenn Hansen, Ph.D. Chief Scientific Officer | 299.2K | 298.8K | — | 93.9K | — | 3.5K | 695.4K | 13.51% | ↗ |
| 31 | 2019 | Gwenn M. Hansen, Ph.D. Chief Scientific Officer | 299.2K | 298.8K | — | 93.9K | — | 3.5K | 695.4K | 13.51% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arthur T. Sands | Chief Executive Officer, President & Director | 1M | — |
| Gwenn Hansen | Chief Scientific Officer | 866.3K | — |
| Johannes Van Houte | Chief Financial Officer | 848.3K | male |
| Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | 815.1K | — |
| John Kuriyan | Founder & Member of Scientific Advisory Board | — | — |
| Pasit Phiasivongsa | Chief Technical Officer | — | — |
| Rita Kwong | Senior Accounting Manager | — | — |
| Arthur Weiss | Founder & Member of Scientific Advisory Board | — | — |
| Christopher Phelps | Senior Vice President & Head of Early Drug Discovery | — | male |
| Jason Kantor | Chief Business Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NRIX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
